文献速递消化道肿瘤放疗

食管癌根治性放疗中同步整合加量概念:结局与毒性

Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity.
PubMed 文献 · Radiat Oncol · 2021-02-01

该单中心回顾性研究分析2012至2018年101例接受根治性放化疗或单纯放疗的食管癌患者,采用同步整合加量(SIB)技术,原发肿瘤和 elective 淋巴结50.4 Gy/28次,宏观肿瘤和淋巴结转移灶58.8 Gy。结果显示1年OS、PFS、LCR分别为63.9%、53.9%、59.9%,3年分别为37.6%、34.5%、36.1%,47.5%患者出现至少一级III°毒性,以吞咽困难为主。结论认为SIB安全可行,结局可接受,可能部分补偿省略的同步化疗。

要点

  • SIB根治性放疗1年OS 63.9%、PFS 53.9%、LCR 59.9%,3年分别为37.6%、34.5%、36.1%。
  • 47.5%患者出现至少一级III°毒性,最常见为吞咽困难(36例,占75%)。
  • SIB可能作为省略同步化疗的部分补偿,需前瞻性研究验证。

核心结论

  • SIB概念在根治性放化疗中安全可行,在该患者队列中结局可接受。
  • SIB放疗可能部分补偿省略的同步化疗,尤其适用于不适合化疗的老年患者。
  • 需要前瞻性研究验证上述结论。

研究设计与样本

  • 单中心回顾性研究,纳入2012至2018年101例食管癌患者。
  • 所有患者接受根治性放化疗或单纯放疗,采用调强放疗。
  • 处方剂量:原发肿瘤和 elective 淋巴结50.4 Gy/28次,宏观肿瘤和淋巴结转移灶SIB 58.8 Gy。
  • 60例(59.4%)接受放化疗,41例(40.6%)接受单纯放疗。
  • 中位随访17个月(范围0-75个月)。

主要发现

  • 1年OS、PFS、LCR分别为63.9%、53.9%、59.9%。
  • 3年OS、PFS、LCR分别为37.6%、34.5%、36.1%。
  • 16例(15.8%)在放疗野内出现局部区域复发。
  • 48例(47.5%)在放疗期间记录到至少一级III°(CTCAE)毒性,其中吞咽困难36例(占75%)。
  • 1例患者发生IV°肺炎。

临床怎么用

  • 对于不适合同步化疗的食管癌患者,可考虑采用SIB根治性放疗作为替代策略。
  • SIB放疗时需关注III°毒性,尤其是吞咽困难。

局限性

  • 回顾性研究设计。
  • 单中心、样本量有限(101例)。
  • 中位随访时间较短(17个月)。
  • 队列主要由老年患者组成,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation therapy and chemoradiation therapy play a major role in the definitive management of esophageal cancer. Survival in esophageal cancer patients is still relatively poor, mostly due to high rates of local recurrence and distant metastases. It is hypothesized that dose escalation in radiotherapy could improve outcomes. Therefore, this retrospective analysis aimed to investigate the outcomes and toxicity in patients treated with local dose escalation by means of using simultaneous integrated boost concepts. METHODS: Between 2012 and 2018, 101 patients with esophageal carcinoma were analyzed in this monocentric, retrospective study. All patients received definitive chemoradiation or radiation therapy alone as intensity modulated radiotherapy. The prescribed dose was 50.4 Gy in 28 fractions to the primary tumor and the elective lymph nodes as well as a simultaneous integrated boost (SIB) with 58.8 Gy to macroscopic tumor and lymph node metastases. Endpoints were overall survival (OS), progression free survival (PFS), local control rate (LCR) and toxicity. RESULTS: 60 patients (59.4%) received chemoradiation, 41 patients (40.6%) radiotherapy alone. The median follow up was 17 months (range 0-75 months). OS, PFS and LCR were at 63.9%, 53.9% and 59.9% after 1 year and 37.6%, 34.5% and 36.1%, respectively after 3 years. 16 patients (15.8%) in total developed a locoregional recurrence within the field of radiation. In 48 patients (47.5%) at least one grade III° (CTCAE) toxicity was documented during radiotherapy, mostly dysphagia (36 pat., 75%). One patient suffered from a grade IV° pneumonia. CONCLUSION: This retrospective analysis demonstrates that a SIB concept in definitive (chemo)radiation therapy is safe and feasible, showing acceptable outcomes in this patient cohort. Considering that this cohort mainly consists of elderly patients not eligible for chemotherapy in many cases, we emphasize the aspect of SIB radiation therapy as potential partial compensation for omitted simultaneous chemotherapy. Prospective studies are needed for validation.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ristau J, Thiel M, Katayama S, et al. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity. Radiat Oncol. 2021. PMID: 33522923. doi:10.1186/s13014-021-01749-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。